annb0t
Top 20
Immutep Limited
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 months 73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration compared to pre-study situation Encouraging preliminary Overall Survival (OS) at the 6-month landmark, with a ...
>>> Read more: Immutepâs Efti in Combination with MSDâs Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory) Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 months 73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration compared to pre-study situation Encouraging preliminary Overall Survival (OS) at the 6-month landmark, with a ...
>>> Read more: Immutepâs Efti in Combination with MSDâs Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
